Procedimentos para o monitoramento populacional de Diaphorina Citri , vetor do Huanglongbing (HLB) dos citros.

Após o registro do agente etiológico do HLB, a bactéria Candidatus liberibacter spp. no Brasil em 2004, o inseto vetor Diaphorina citri (Hemiptera: Psyllidae) antes considerado uma praga secundária dos citros, ganhou o status de inseto-praga de grande importância

Monitoramento populacional de Diaphorina citri Kuwayama, 1908 (Hemiptera: Liviidae) em cinco municípios do Recôncavo da Bahia.

O psilídeo Diaphorina citri é um importante vetor da bactéria Candidatus liberibacter spp., causadora do HLB (Huaglongbing), doença mais devastadora dos citros, assumindo, assim, o status de principal praga nessa cultura. O agente etiológico do HLB foi registrado no Brasil em 2004, primeiramente em São Paulo e, posteriormente, em Minas Gerais e Paraná

Using Landsat 8 image time series for crop mapping in a region of Cerrado, Brazil.

Abstract: The objective of this research is to classify agricultural land use in a region of the Cerrado (Brazilian Savanna) biome using a time series of Enhanced Vegetation Index (EVI) from Landsat 8 OLI. Phenological metrics extracted from EVI time series, a Random Forest algorithm and data mining techniques are used in the process of classification. The area of study is a region in the Cerrado in a region of the municipality of Casa Branca, São Paulo state, Brazil. The results are encouraging and demonstrate the potential of phenological parameters obtained from time series of OLI vegetation indices for agricultural land use classification

SRC inhibition prevents P-cadherin mediated signaling and function in basal-like breast cancer cells

BACKGROUND: Basal-like breast cancer (BLBC) is a poor prognosis subgroup of triple-negative carcinomas that still lack specific target therapies and accurate biomarkers for treatment selection. P-cadherin is frequently overexpressed in these tumors, promoting cell invasion, stem cell activity and tumorigenesis by the activation of Src-Family kinase (SRC) signaling. Therefore, our aim was to evaluate if the treatment of BLBC cells with dasatinib, the FDA approved SRC inhibitor, would impact on P-cadherin induced tumor aggressive behavior. METHODS: P-cadherin and SRC expression was evaluated in a series of invasive Breast Cancer and contingency tables and chi-square tests were performed. Cell-cell adhesion measurements were performed by Atomic Force Microscopy, where frequency histograms and Gaussian curves were applied. 2D and 3D cell migration and invasion, proteases secretion and self-renew potential were evaluated in vitro. Student's t-tests were used to determine statistically significant differences. The cadherin/catenin complex interactions were evaluated by in situ proximity-ligation assay, and statistically significant results were determined by using Mann-Whitney test with a Bonferroni correction. In vivo xenograft mouse models were used to evaluate the impact of dasatinib on tumor growth and survival. ANOVA test was used to evaluate the differences in tumor size, considering a confidence interval of 95%. Survival curves were estimated by the Kaplan-Meier's method, using the log-rank test to assess significant differences for mice overall survival. RESULTS: Our data demonstrated that P-cadherin overexpression is significantly associated with SRC activation in breast cancer cells, which was also validated in a large series of primary tumor samples. SRC activity suppression with dasatinib significantly prevented the in vitro functional effects of P-cadherin overexpressing cells, as well as their in vivo tumorigenic and metastatic ability, by increasing mice overall survival. Mechanistically, SRC inhibition affects P-cadherin downstream signaling, rescues the E-cadherin/p120-catenin complex to the cell membrane, recovering cell-cell adhesion function. CONCLUSIONS: In conclusion our findings show that targeting P-cadherin/SRC signaling and functional activity may open novel therapeutic opportunities for highly aggressive and poor prognostic basal-like breast cancer.This work was funded by Laço Grant 2014, by FEDER - Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by FCT - Fundação para a Ciência e a Tecnologia/ Ministério da Ciência, Tecnologia e Ensino Superior under the projects PTDC/SAU-GMG/120049/ 2010-FCOMP-01-0124-FEDER-021209, PEst-C/SAU/LA0003/2013, NORTE-01- 0145-FEDER-000029 and POCI-01-0145-FEDER-016390. FCT funded the research grants of ASR (SFRH/BPD/75705/2011), ARN (SFRH/BD/100380/2014), BS (SFRH/ BPD/104208/2014), AFV (SFRH/BPD/90303/2012), as well as JP with Programa IFCT 2013 (FCT Investigator). IPATIMUP integrates the i3S Research Unit, which is partially supported by FCT in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274)